Business Wire

CSL-VIFOR

19.8.2022 07:02:13 CEST | Business Wire | Press release

Share
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc . (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/

“The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a high unmet medical need for a targeted therapy to treat moderate-to-severe pruritus, and we are convinced that Kapruvia® can provide relief to many suffering from this heavy burden. We are very committed to making this therapy available to patients as soon as possible.”

“We are pleased that Kapruvia® is now approved in Switzerland for hemodialysis patients who are suffering from CKD-associated pruritus,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “As Cara Therapeutics continues on the path toward becoming the leader in the treatment of chronic pruritus, we are working with our partner VFMCRP to ensure this first-of-its-kind therapy is available to healthcare providers and patients across the globe who greatly need a treatment option.”

Swissmedic approval was supported by positive data from two pivotal phase-III trials – KALM-1, conducted in the U.S. (New England Journal of Medicine 2020; 382:222-232), and the global KALM-2, as well as supportive data from an additional 32 clinical studies.

Kapruvia® has been submitted in Switzerland as part of an Access Consortium procedure together with Canada (approved in August 2022), as well as Australia and Singapore. Regulatory decisions in these two markets are expected in the second half of 2022.

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com .

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter , LinkedIn and Instagram .

About Chronic Kidney Disease-associated Pruritus

CKD-associated pruritus is an intractable systemic itch condition that occurs with high frequency and intensity in patients with chronic kidney disease undergoing dialysis. Pruritus has also been reported in patients with stage III-V CKD who are not on dialysis. The majority of dialysis patients (approximately 60 to 70%) report pruritus, with 30 to 40% reporting moderate or severe pruritus.1,2,3 Recent data from the ITCH National Registry Study showed that among those with pruritus, approximately 59% experienced symptoms daily or nearly daily for more than a year. Given its association with CKD/ESRD, most afflicted patients will continue to have symptoms for months or years, with currently employed antipruritic treatments, such as antihistamines and corticosteroids, unable to provide consistent, adequate relief. Moderate-to-severe chronic pruritus has repeatedly been shown to directly decrease quality of life, contribute to symptoms that impair quality of life (such as poor sleep quality), and is associated with depression.4 CKD-associated pruritus is also an independent predictor of mortality and the risk for hospitalization among hemodialysis patients.

Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the potential regulatory approval of difelikefalin solution for injection and the potential timeline for EMA review and approval of the MAA and the potential of difelikefalin solution for injection to be a therapeutic option for CKD-aP in dialysis dependent patients. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara's filings with the Securities and Exchange Commission, including the "Risk Factors" section of Cara's Quarterly Report on Form 10-Q for the quarter ended 30 September 2021 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Cara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

References:

1 Pisoni RL, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2006; 21:3495-3505.
2 Ramakrishnan K, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. International Journal of Nephrology and Renovascular Disease. 2014; 7: 1-12.
3 Sukul et al. Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. Kidney Med. 2020 Nov 21;3(1):42-53.
4 Mathur VS, et al. A longitudinal study of Uremic Pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010; 5(8):1410-1419.

# # #

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Klarna Reports Third Quarter 2026 Results17.11.2026 13:45:00 CET | Press release

Klarna Group plc (NYSE: KLAR), the everyday finance network, today reported third quarter 2026 results. GMV reached $36.1 billion (+10% YoY), revenue $1.0 billion (+12% YoY), transaction margin dollars (TMD) $371 million (+32% YoY), and adjusted operating income $21 million (+$35m YoY). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116206092/en/ "Q3 was our fourth straight quarter with revenue above 1 billion dollars and positive adjusted operating income. We are keeping more of each dollar we process through our everyday finance network: transaction margin is now 37% of revenue, up from 31% a year ago. Looking ahead, we’re finishing the year strong as we are running on track with, or ahead of, all our full year outlook.” Sebastian Siemiatkowski, CEO & Co-Founder, Klarna Klarna’s full earnings release is available at the Quarterly Results section of its website at https://investors.klarna.com/financials/quarterly-results

Would You Let AI Manage Your Next Trip?17.11.2026 13:06:00 CET | Press release

New research suggests AI agents could change how travelers choose airlines and hotels by 2032The Intelligent Journey 2032 explores four directions travel could take by early in the next decade, and how technology, particularly AI, will connect travelers with airlines, airports, hotels and other travel companies.The study suggests the future will be defined by travelers deciding what they are willing to delegate, with clear consent, spending limits, and the ability to retain control as key considerations.It also identifies travel orchestration as the strategic prize for the industry, as AI could reshape travel commerce, and shift value toward those able to coordinate the entire journey across suppliers, payments, identity, disruption and service. AI is already transforming the traveler journey, helping people discover, plan and navigate their trips. The question is how far travelers will let AI make decisions for them in the future: booking, paying, changing plans and recovering from di

Iconic Raises $10M to Build Software That Understands the World’s Biggest Projects17.11.2026 13:01:00 CET | Press release

Iconic has raised $10 million in seed funding led by Peak Capital, with participation from Bridford Group, Common Magic, Graduate Ventures, NP-Hard, and Tiny VC. Since its founding in mid-2025, Iconic has signed five clients in energy, infrastructure, and AI infrastructure: a global energy major, a leading European utility, a major European airport, a European rail infrastructure owner, and a global contractor building semiconductor fabs and data centers. Each spends over $1 billion annually on capital projects. An estimated $15 trillion is invested in capital projects annually, yet fewer than 3% are delivered on time, on budget, and to plan. Capital projects rarely fail because of engineering complexity, but because decisions are made without a complete understanding of the project. Information is fragmented across documents and systems shared by owners, contractors, and engineering firms. Decisions are hard to reverse, with consequences lasting years through delays, claims, and cost

Quaise Energy Signs 50 MW Geothermal Power Purchase Agreement with Google17.11.2026 12:50:00 CET | Press release

Agreement advances development of commercial-scale superhot geothermal, will supply carbon-free energy to Oregon communities as early as 2030 Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that Google has signed a power purchase agreement (PPA) for 50 megawatts (MW) of superhot geothermal power from Project Obsidian, Quaise’s flagship project in Central Oregon. Once online, this always-on, carbon-free energy is slated to support Google’s existing data center operations in The Dalles, Ore. and the region’s communities. The agreement will help catalyze the commercial development of superhot geothermal energy, providing benefits for ratepayers and helping protect the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117923219/en/ Beginning as early as 2030, Google will purchase 50 MW of power from Project Obsidian. The initial phase of development will use convention

Nowhere to Sit, Nothing to Do: Europe’s Biggest Airports Fall Short for Passengers17.11.2026 12:24:00 CET | Press release

AirHelp data shows that nearly half of Europe’s biggest airports score below the global average for both seating and entertainment. One in four of Europe’s 50 biggest airports scores below the global average on all four parts of the experience passengers rated, according to AirHelp data covering 279 airports worldwide. Passengers rated each airport on wait times, restaurants, seating and entertainment. Twelve airports, including Dublin, Manchester, Lisbon, London Luton and Milan Bergamo, came in below the global average on all four. Only four beat all four averages: Zurich, Warsaw, Naples and Ankara. Entertainment is the weak spot almost everywhere Entertainment was the lowest-rated part of the experience at 45 of the 50 airports, averaging 6.5 out of 10, with more than half of the airports falling below the global average of 6.7. Seven airports scored less than 6, including Manchester, Stansted, Dublin and Oslo. The data also suggests that passengers who can’t find a seat usually have

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye